

Abstract Title: UPDATED RESULTS OF THE ASPEN TRIAL FROM A COHORT OF PATIENTS WITH WILD-TYPE *MYD88* WALDENSTRÖM MACROGLOBULINEMIA

Authors: A. Tedeschi, MD¹; M. Dimopoulos, MD²; R.G. Sanz, MD, PhD³; H-P. Lee, MBChB, FRACP, FRCPA⁴; M. Trneny, MD, CSc⁵; M. Varettoni, MD⁶; S. Opat, MBBS, FRACP, FRCPA^{7,8}; S. D'Sa, MD, MRCP, FRCPath⁹; R.G. Owen, MD¹⁰; G. Cull, MB, BS, FRACP, FRCPA^{11,12}; S. Mulligan, MBBS, PhD, FRACP, FRCPA¹³; J. Czyz, MD, PhD^{14,15}; J. Castillo, MD^{16,17}; M. Motta, MD¹⁸; T. Siddiqi, MD¹⁹; M.G. Mesa, MD²⁰; M.G. Gorrochategui, MD²¹; D. Talaulikar, PhD FRACP, FRCPA, MBBS²²; P.L. Zinzani, MD, PhD²³; E. Askari, MD²⁴; S. Grosicki, MD, PhD²⁵; A. Oriol, MD²⁶; J. Kloczko, MD²⁷; C. Buske, MD²⁸; V. Leblond, MD²⁹; W.Y. Chan, PhD³⁰; J. Schneider, PhD³⁰; A. Cohen, MD, PhD³⁰; J. Huang, MD³⁰; and C.S. Tam, MBBS, MD, FRACP, FRCPA^{31, 32, 33, 34}

Affiliations: ¹ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy; ²National and Kapodistrian University of Athens, Athens, Greece; ³Hospital Universitario de Salamanca, Salamanca, Spain; ⁴Flinders Medical Centre, Adelaide, South Australia, Australia; ⁵Všeobecná fakultní nemocnice v Praze, Prague, Czech Republic; ⁶Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; ⁷Monash Health, Clayton, Victoria, Australia; ⁸Monash University, Clayton, Victoria, Australia; ⁹University College London Hospital Foundation Trust, London, United Kingdom; ¹⁰St James University Hospital, Leeds, United Kingdom; ¹¹Sir Charles Gairdner Hospital, Perth, Western Australia, Australia; ¹²University of Western Australia, Perth, Western Australia, Australia; ¹³Royal North Shore Hospital, Sydney, New South Wales, Australia; ¹⁴Szpital Uniwersytecki nr 2 im dr. Jana Bizuela, Kujawsko-pomorskie, Bydgoszcz, Poland; ¹⁵Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Bydgoszcz, Poland; ¹⁶Dana-Farber Cancer Institute, Boston, MA, USA; ¹⁷Harvard Medical School, Boston, MA, USA; ¹⁸AO Spedali Civili di Brescia, Lombardia, Italy; ¹⁹City of Hope National Medical Center, Duarte, CA, USA; ²⁰Hospital Universitario Vall d'Hebrón, Barcelona, Spain; ²¹Hospital de La Santa Creu i Sant Pau, Barcelona, Spain; ²²Australian National University, Canberra, ACT, Australia; ²³Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy; ²⁴Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain; ²⁵Department of Hematology and Cancer Prevention, Health Sciences Faculty, Medical University of Silesia, Katowice, Poland; ²⁶Institut Català d'Oncologia-Hospital Universitari Germans Trias i Pujol, Barcelona, Spain; ²⁷Uniwersytecki Szpital Kliniczny w Białymstoku, Podlaskie, Poland; ²⁸CCC Ulm - Universitätsklinikum Ulm, Ulm, Baden-Württemberg, Germany; ²⁹Sorbonne University, Pitié Salpêtrière Hospital, Paris, France; ³⁰BeiGene USA, Inc., San Mateo, CA, USA; ³¹Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; ³²St Vincent's Hospital, Fitzroy, Victoria, Australia; ³³University of Melbourne, Parkville, Victoria, Australia; and ³⁴Royal Melbourne Hospital, Parkville, Victoria, Australia

Introduction: Inhibitors of Bruton's tyrosine kinase (BTK) have shown significant activity in patients with *MYD88*-mutation–positive (*MYD88*^{mut+}) Waldenström macroglobulinemia (WM). However, lower response rates and shorter progression-free survival have been reported in patients with WM who lack such mutations. The ASPEN trial (NCT03053440) evaluated zanubrutinib, a potent and selective next-generation BTK inhibitor, in patients with *MYD88*^{mut+} and wild-type *MYD88* (*MYD88*^{WT}) WM. The safety and efficacy of zanubrutinib in patients with *MYD88*^{WT} WM from the ASPEN trial are presented.

Methods: In the ASPEN trial, *MYD88* gene mutations were assessed in bone marrow at study entry by a central laboratory (NeoGenomics). Based on these results, patients were assigned to cohort 1 (*MYD88*^{mut+}) or cohort 2 (*MYD88*^{WT} or unknown mutation status). In cohort 2, patients received zanubrutinib 160 mg twice daily until disease progression.

Results: In total, 28 patients were enrolled in cohort 2, of which 26 were centrally confirmed as *MYD88*^{WT}. Median age of patients was 72 years; five patients were treatment-naïve and 23 patients had relapsed/refractory (≥ 1 prior therapy) WM. Most patients had intermediate-risk (39.3%) or high-risk (42.9%) disease, as defined by the International Prognostic Scoring System for WM. At a median follow-up of 17.9 months, two patients discontinued zanubrutinib due to adverse events (AEs) and six experienced disease progression; there were no cases of disease transformation. In 26 confirmed *MYD88*^{WT} patients, the overall response rate by independent central review was 80.8%, with a major response rate of 50.0%, including a very good partial response rate of 26.9% (**Table**). The progression-free survival rate at 12 months was 72.4%. The most frequently reported AEs were diarrhea, anemia, contusion, pyrexia, and upper respiratory tract infection. Major hemorrhage was reported in two patients, and atrial fibrillation was reported in one patient. There were no fatal AEs.

Conclusions: Zanubrutinib showed clinically meaningful antitumor activity, including achieving major responses and durability of responses, and was considered well tolerated with a low discontinuation rate due to AEs in patients with *MYD88*^{WT} WM.

Table. Best Overall Response by Independent Central Review in Patients With *MYD88*^{WT} WM

	Treatment-naïve WM (n=5)	Relapsed/refractory WM (n=21)	Overall (N=26)
Median follow-up, months	19.3	17.1	17.9
Best overall response, n (%)			
Complete response	0	0	0
Very good partial response	1 (20.0)	6 (28.6)	7 (26.9)
Partial response	1 (20.0)	5 (23.8)	6 (23.1)
Minor response	2 (40.0)	6 (28.6)	8 (30.8)
Stable disease	1 (20.0)	3 (14.3)	4 (15.4)
Progressive disease	0	1 (4.8)	1 (3.8)

WM, Waldenström macroglobulinemia; WT, wild-type.